文献速递胸部肿瘤头颈与中枢神经肿瘤骨软组织肉瘤与黑色素瘤

mTOR与HDAC抑制剂汇聚于TXNIP/硫氧还蛋白通路引发灾难性氧化应激并消退RAS驱动肿瘤

mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors.
PubMed 文献 · Cancer Discov · 2017-09-29

本研究在NF1突变肿瘤中发现,mTOR与HDAC抑制剂联合可通过协同影响染色质和转录,汇聚于TXNIP/硫氧还蛋白抗氧化通路,引发灾难性氧化应激,在体内缩小肿瘤并杀死NF1突变及KRAS突变非小细胞肺癌细胞,为缺乏靶向驱动基因的恶性肿瘤提供有前景的治疗组合。

要点

  • mTOR与HDAC抑制剂联合通过TXNIP/硫氧还蛋白通路引发灾难性氧化应激。
  • 该联合在体内缩小NF1突变神经系统恶性肿瘤并杀死NF1/KRAS突变NSCLC。
  • TXNIP通过抑制硫氧还蛋白并激活ASK1触发细胞死亡。

核心结论

  • mTOR与HDAC抑制剂联合通过汇聚于TXNIP/硫氧还蛋白抗氧化通路引发灾难性氧化应激,杀死NF1突变肿瘤并在体内缩小肿瘤。
  • 该联合也为NF1突变和KRAS突变非小细胞肺癌提供有前景的治疗组合。

研究设计与样本

  • 临床前研究,识别并验证mTOR与HDAC抑制剂联合杀伤NF1突变肿瘤的机制。

主要发现

  • mTOR与HDAC抑制剂通过协同影响染色质和转录,汇聚于TXNIP/硫氧还蛋白抗氧化通路。
  • TXNIP通过抑制硫氧还蛋白并激活ASK1触发细胞死亡。
  • 该联合在体内缩小NF1突变神经系统恶性肿瘤,并杀死NF1突变和KRAS突变非小细胞肺癌。

临床怎么用

  • 为NF1或RAS突变等当前缺乏有效疗法的恶性肿瘤提供有前景的mTOR/HDAC抑制剂联合治疗策略。
  • 选择性增强氧化应激可能更广泛地用于开发癌症疗法。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Although agents that inhibit specific oncogenic kinases have been successful in a subset of cancers, there are currently few treatment options for malignancies that lack a targetable oncogenic driver. Nevertheless, during tumor evolution cancers engage a variety of protective pathways, which may provide alternative actionable dependencies. Here, we identify a promising combination therapy that kills NF1-mutant tumors by triggering catastrophic oxidative stress. Specifically, we show that mTOR and HDAC inhibitors kill aggressive nervous system malignancies and shrink tumors in vivo by converging on the TXNIP/thioredoxin antioxidant pathway, through cooperative effects on chromatin and transcription. Accordingly, TXNIP triggers cell death by inhibiting thioredoxin and activating apoptosis signal-regulating kinase 1 (ASK1). Moreover, this drug combination also kills NF1-mutant and KRAS-mutant non-small cell lung cancers. Together, these studies identify a promising therapeutic combination for several currently untreatable malignancies and reveal a protective nodal point of convergence between these important epigenetic and oncogenic enzymes.Significance: There are no effective therapies for NF1- or RAS-mutant cancers. We show that combined mTOR/HDAC inhibitors kill these RAS-driven tumors by causing catastrophic oxidative stress. This study identifies a promising therapeutic combination and demonstrates that selective enhancement of oxidative stress may be more broadly exploited for developing cancer therapies. Cancer Discov; 7(12); 1450-63. ©2017 AACR.This article is highlighted in the In This Issue feature, p. 1355.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Malone CF, Emerson C, Ingraham R, et al. mTOR and HDAC Inhibitors Converge on the TXNIP/Thioredoxin Pathway to Cause Catastrophic Oxidative Stress and Regression of RAS-Driven Tumors. Cancer Discov. 2017. PMID: 28963352. doi:10.1158/2159-8290.CD-17-0177

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。